If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor.
Starting July 1, alternatives to the world’s top-selling drug are expected to flood the market, some at dramatically lower prices.
Mark Cuban’s Cost Plus Drugs, the company the Dallas billionaire is backing to disrupt the pharmaceutical industry, will start selling Humira alternative Yusimry at $569 for a 40-milligram dose (typically taken every two weeks). Humira can cost more than $3,600 a dose.
